About duvelisib
PI3K-delta and PI3K-gamma inhibitor
Used for
- Treats certain adults with chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two previous treatments.
- Treats follicular lymphoma after at least two previous systemic treatments.
Usual adult dose
25 mg by mouth twice daily for CLL/SLL; 25 mg twice daily for follicular lymphoma, until progression or unacceptable toxicity.
Common side effects
- Diarrhea or inflammation of the bowel
- Infections, including pneumonia
- Low blood cell counts
- Rash, fatigue, or nausea
Important warnings
- Can cause serious or fatal infections, diarrhea or bowel inflammation, skin reactions, and lung inflammation.
- Blood counts, liver tests, and infection symptoms require monitoring.
- Avoid live vaccines during treatment.
- Treatment should be managed by a clinician experienced in cancer medicines.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for one month after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one month after the last dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, can increase duvelisib exposure; dose adjustment may be needed.
- Strong CYP3A4 inducers, such as rifampin, can reduce exposure and should generally be avoided.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.